Kronos Bio, Inc.·4

Feb 23, 8:07 PM ET

Lin Charles Y 4

4 · Kronos Bio, Inc. · Filed Feb 23, 2024

Insider Transaction Report

Form 4
Period: 2024-02-21
Lin Charles Y
SR VP, RESEARCH & DEVELOPMENT
Transactions
  • Sale

    Common Stock

    2024-02-21$1.05/sh12,036$12,685234,603 total
Footnotes (2)
  • [F1]Represents shares sold to satisfy estimated tax withholding obligations upon the settlement of restricted stock units.
  • [F2]The weighted average sale price for the transaction reported was $1.0539, and the range of prices were between $1.02 to $1.11. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Documents

1 file
  • 4
    form4-02242024_010239.xmlPrimary